skip to content

Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.